Research reviewed by Gram suggests that obesity is linked to better survival after immunotherapy in men, but in women the benefit appears only after age 55. In a 2026 study, male mice with diet-induced obesity responded better to treatment, showing that sex and hormones shape this effect.
Obesity is usually seen as a risk factor for cancer, yet some studies have found that people with obesity respond better to immune checkpoint inhibitors, a type of immunotherapy. According to research reviewed by Gram, this effect may depend on sex and hormones. In a large analysis across many cancer types, obesity, defined as a body mass index (BMI) of 30 or higher, was linked to longer survival after immunotherapy in men. In women, the link appeared only in those aged 55 and older, after menopause. Experiments in mice supported these patterns. Obese male mice responded better to treatment, while obese female mice showed immune changes that appeared to weaken the treatment’s effect. Removing the ovaries in female mice reduced these changes and increased tumor-fighting immune cells. The researchers concluded that the so-called obesity paradox in immunotherapy is shaped by sex and hormonal status. These findings are early and should not change cancer care on their own.
Key Statistics
A 2026 pan-cancer analysis published in The Journal of Clinical Investigation found that obesity, defined as a BMI of 30 or higher, was linked to better survival after immune checkpoint inhibitor treatment only in male patients.
In the same 2026 study, obesity was linked to better outcomes in female cancer patients only among those aged 55 and older, after menopause.
A 2026 mouse study reported that only male mice with diet-induced obesity responded better to immunotherapy, while obese female mice showed more tumor-supporting M2 macrophages.
The Quick Take
- What they studied: Does body weight affect how well cancer immunotherapy works, and does this depend on whether a person is male or female, and on hormone levels?
- Who participated: The researchers looked at patient records from many types of cancer and grouped people by sex and BMI. They also studied mice that were fed a high-fat diet to make them obese. The exact number of people and mice was not listed in the summary provided.
- Key finding: In the patient analysis, people with obesity (BMI of 30 or higher) lived longer after immunotherapy only if they were male. In women, the benefit of obesity appeared only after menopause, at age 55 or older. In mice, only obese males responded better to treatment.
- What it means for you: This research suggests that the link between body weight and immunotherapy success is not the same for everyone. It does not mean that gaining weight will help treatment work. Anyone with cancer should talk with their oncology team before making changes based on body weight.
The Research Details
The study combined several types of research. First, the team reviewed data from patients with many different cancers who received immune checkpoint inhibitors, a treatment that helps the immune system attack tumors. They sorted patients by sex and BMI to see how body weight related to survival in each group. This kind of broad review is called a pan-cancer analysis, meaning it looks across many cancer types at once.
Second, the researchers used mice that were fed a high-fat diet until they became obese. Mice are often used in early research because their immune systems and tumors can be studied in controlled ways. Some obese female mice had their ovaries removed, a procedure called ovariectomy, to test whether the female hormone estrogen was driving the immune changes.
Third, the team analyzed metabolites, which are small chemical products of the body’s processes, in the obese mice. They compared these chemical profiles between males and females to look for differences that might explain the results.
Combining human patient data with animal experiments helps test whether a pattern seen in people has a plausible biological cause. The patient data show what happens in real life, while the mouse experiments can test specific explanations, such as the role of hormones and immune cells. Using both types of evidence makes the findings more convincing than either approach alone.
The study was published in The Journal of Clinical Investigation, a well-known peer-reviewed journal in medicine. Using several methods, including patient data, animal experiments, and chemical profiling, adds strength. However, the summary does not state the number of patients or mice, which makes it harder to judge how precise the results are. Patient data analyses also cannot prove cause and effect, because people who differ in weight may also differ in other health factors.
What the Results Show
The patient analysis found that obesity was linked to better survival after immune checkpoint inhibitor treatment in male patients. Obesity was defined as a BMI of 30 or higher. This pattern did not appear in the same way for female patients as a whole.
When the researchers looked at women more closely, they found that obesity was linked to better outcomes only in women aged 55 and older. This age roughly marks the years after menopause, when hormone levels, especially estrogen, have dropped. This suggests that hormones may play a role in how body weight affects treatment response.
The mouse experiments supported these patient findings. Only male mice with diet-induced obesity responded better to immunotherapy. In obese female mice, the researchers found more tumor-associated macrophages, which are immune cells that can be pushed into a state (called M2) that helps tumors grow and hide from the immune system. When these female mice had their ovaries removed, the M2 shift decreased, and more T cells, which are immune cells that attack tumors, moved into the tumor after immunotherapy.
Finally, the chemical profiles of obese male and female mice were different. This suggests that sex affects how the body processes fats, sugars, and other compounds, and that these differences may influence the immune environment around tumors.
The researchers found that the tumor environment, meaning the tissue and immune cells surrounding a tumor, changed differently depending on sex and obesity. These changes help explain why the same body weight may help one person’s treatment work better and not help another’s. The metabolic differences between males and females also suggest that treatment responses may be shaped by more than just immune cells. Overall, the study points to hormones and body chemistry as key parts of the story, rather than body weight alone.
Earlier studies have described an obesity paradox in cancer immunotherapy, where people with higher body weight sometimes respond better to treatment than thinner patients. Some earlier work also hinted that sex might matter, but this study tested the question more directly by separating results by sex, BMI, and menopausal status. The findings build on that earlier work and suggest the paradox is not uniform across all people.
The most important limitation is that this research does not show that obesity itself causes better treatment results. Patient data can reveal patterns, but many other factors, such as cancer stage, other health conditions, medications, and lifestyle, may affect outcomes. Mouse studies also do not always match human biology, so results in mice cannot be assumed to apply to people. The summary also does not state the number of participants or mice, which limits how confidently the results can be judged. Finally, the study focused on specific immunotherapy drugs, so the findings may not apply to all cancer treatments.
The Bottom Line
Research shows that sex and hormone status can change how body weight relates to immunotherapy outcomes in both mice and patient data. Confidence in the basic pattern is moderate because it appears in two different types of evidence. However, no one should try to gain weight to improve cancer treatment. Current evidence is too early to guide medical decisions, so patients should follow guidance from their own cancer care team.
People receiving or considering immune checkpoint inhibitors, oncologists, researchers studying cancer immunology, and anyone interested in how sex and hormones affect health may find this research relevant. People without cancer should not change their diet or weight based on these results. Individuals with obesity who are being treated for cancer should discuss their specific situation with their doctor rather than assume their outcome will be better or worse.
These findings are early and are not yet part of standard care. It may take years of additional clinical trials before doctors could use sex, BMI, or hormonal status to guide treatment choices. Anyone currently being treated should expect their care plan to stay the same unless their medical team recommends a change.
Frequently Asked Questions
Does being overweight help cancer immunotherapy work better?
Research shows that the link between body weight and immunotherapy results depends on sex and hormones. In a 2026 analysis, obesity with a BMI of 30 or higher was linked to better survival in men, and in women only after age 55. These findings are early, and weight should not be changed without medical advice.
Why would obesity affect immunotherapy differently in men and women?
Mouse experiments suggest hormones play a key role. Obese female mice had more tumor-supporting M2 macrophages, and removing their ovaries reduced these cells and increased tumor-attacking T cells. Male and female mice also showed different body chemistry profiles, which may shape how the immune system responds to treatment.
Does menopause change how body weight affects cancer treatment?
According to research reviewed by Gram, obesity was linked to better immunotherapy outcomes in women only when they were aged 55 and older. This age roughly marks the years after menopause, when estrogen levels drop. Researchers think hormone changes may explain this pattern, but more studies are needed to confirm it.
Should I talk to my doctor about this study before my cancer treatment?
Yes, a discussion with your oncology team is the best next step. This early research is not yet used in clinical care. Your doctor can explain how your BMI, sex, age, and hormone status apply to your specific treatment plan and whether any changes are appropriate for you.
Want to Apply This Research?
- Track BMI, waist circumference, and weight once a week, and log menopausal status or age, so users can see long-term patterns. Users with a cancer diagnosis should also record treatment start dates and any side effects, and share the data with their care team.
- Encourage users to schedule a conversation with their doctor about how their weight, sex, and hormone status may relate to their treatment plan. Suggest keeping a simple health journal of questions to bring to appointments. Avoid prompts that encourage weight gain or weight loss for cancer treatment purposes.
- Use monthly check-ins to review BMI, waist measurements, energy levels, and any treatment-related symptoms. Over time, the app can show trends that users can discuss with their healthcare providers. Users should be reminded that the app is for tracking, not diagnosis, and that clinical decisions belong to their medical team.
This article summarizes early research, including mouse experiments and an analysis of patient data, and is for general education only. It is not medical advice. The findings do not show that body weight causes better or worse cancer outcomes, and they should not lead anyone to change their diet, weight, or treatment. Anyone with cancer should discuss their individual situation with their oncology team before making any decisions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.